Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
Volume: 37, Issue: 15_suppl, Pages: TPS5090 - TPS5090
Published: May 20, 2019
Abstract
TPS5090 Background: Responses to checkpoint inhibitor (CPI) monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) have been limited. This is in part attributed to low tumour mutational burden (TMB) and low tumour infiltrating lymphocytes (TILs). Previously ~20% patients with prostate cancer have demonstrated high TILs or TMB 1 . We hypothesize that patients with higher TMB due to mismatch repair deficiency (dMMR)...
Paper Details
Title
Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).
Published Date
May 20, 2019
Journal
Volume
37
Issue
15_suppl
Pages
TPS5090 - TPS5090
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History